Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denecimig in Acquired Haemophilia A
NCT07830732Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of denecimig in acquired haemophilia A (AHA), sponsored by Novo Nordisk. Primary endpoint: Number of treated bleeds at 12 weeks. Started Oct 2026; status: recruiting.
02
Drugs
denecimig
03
Conditions
acquired haemophilia A (AHA)
Beyond the preview
Go deeper on NCT07830732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830732.